Abbisko Signs an Exclusive License Agreement with Sperogenix to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
Shots:
- Abbisko to receive upfront- milestones and royalties on net sales of the therapy & hold the rights for all other countries & indications. Sperogenix gets an exclusive right to develop- manufacture & commercialize ABSK021 in mainland China- Hong Kong SAR and Macao SAR for non-oncology rare neurological diseases
- Sperogenix will be responsible for the development of ABSK021 in ALS includes pre/ clinical studies- registration & commercialization of the product in the Sperogenix Territory
- ABSK021 is a selective CSF-1R antagonist. The P-Ib trial has initiated to evaluate safety- tolerability & PK of ABSK021 in China & the US while preliminary data demonstrate that ABSK021 was well tolerated
| Ref: PR Newswire | Image: Abbisko
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com